Bristol, England – New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease. The University of Bristol-led research is published in Cardiovascular Diabetology. Diabetes, a disease which results in uncontrolled blood glucose levels, is estimated to affect one...
treatment News
Dietary management drugs have transformed Type 2 diabetes care, but daily injection routines are challenging for some patients. A new hydrogel could mean shots just three times a year. Stanford, CA – Materials engineers at Stanford University have developed a novel hydrogel drug delivery system that transforms daily or...
Turku, Finland – Cutaneous squamous cell carcinoma (cSCC), also known as the squamous cell carcinoma of the skin, is the most common form of metastatic skin cancer. The incidence of cSCC is increasing worldwide with millions of new cases diagnosed each year. The prognosis of metastatic cSCC is poor as...
TMC207 is a safe and effective drug for the treatment of multidrug-resistant tuberculosis (TB), the results of a randomised, placebo-controlled trial published in the June 4th edition of the New England Journal of Medicine have shown. Patients who received the drug were significantly more likely to have a negative culture...
SAN DIEGO – Non-Hispanic Black patients with acute myeloid leukemia (AML) are living longer, now that new therapies are available, according to a study presented by researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center at the 65th American Society of Hematology (ASH)...
Baltimore, Maryland – A so-called pathological protein long associated with Parkinson’s disease has been found in a new study to trigger cells to increase protein synthesis, an event that eventually kills the subset of brain cells that die off in this neurodegenerative condition. Researchers from the Johns Hopkins University School...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced new interim data from two studies of Evrysdi® (risdiplam); JEWELFISH and RAINBOWFISH. Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously treated...
New York, NY – Addressing Brain Health in Adults With Intellectual Disabilities and Developmental Disabilities: A Companion to the KAER Toolkit for Primary Care Providers is a new publication from the Gerontological Society of America (GSA) designed to address the needs of adults with intellectual and developmental disabilities (I/DD) who...
TEL AVIV, Israel — SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, has initiated a clinical trial using its proprietary therapy, SCI-210, at Soroka Medical Center, Israel, targeting Autism Spectrum Disorder (ASD)...
CHATHAM, NJ – Tonix Pharmaceuticals, Inc. (NASDAQ:TNXP) appears to have a potential new weapon against fibromyalgia for the 6-12 million adults in America suffering from its debilitating effects. It has to do with sleep quality, not sleep quantity. Tonix’s candidate drug TNX-102 SL*, which just completed its second successful Phase 3...